SCHEMBL7215697

SCHEMBL7215697

C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC(c5ccc(-c6cccnc6)cc5)[C@@H]43)[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 6/20 0.38
▸ NR3C1 P04150 3/20 0.36
▸ LMNA P02545 2/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ ABCB11 O95342 2/20 0.36
▸ TSHR P16473 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ ESR1 P03372 1/20 0.36
▸ SHBG P04278 1/20 0.36
▸ ADRA2A P08913 1/20 0.36
▸ SLC6A4 P31645 1/20 0.36
▸ CYP17A1 P05093 5/20 0.36
▸ CYP21A2 P08686 1/20 0.36
▸ CYP19A1 P11511 1/20 0.36
▸ AR P10275 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7532215 0.83 PGR (0.40) PGRNR3C1LMNACYP3A4ABCB11
SCHEMBL5498124 0.82 PGR (0.49) PGRNR3C1LMNACYP3A4ABCB11
SCHEMBL8542951 0.82 PGR (0.41) PGRCYP17A1CYP21A2CYP19A1
SCHEMBL8538436 0.73 CYP19A1 (0.35) PGRHIF1AALDH1A1SHBGCYP17A1
SCHEMBL5700112 0.72 CYP3A4 (0.65) PGRNR3C1LMNACYP3A4ABCB11
SCHEMBL5495772 0.71 AR (0.72) PGRNR3C1AR
SCHEMBL5499361 0.70 NR3C1 (0.41) PGRNR3C1LMNACYP3A4CYP17A1
SCHEMBL5496193 0.69 PGR (0.54) PGRNR3C1LMNACYP3A4ABCB11
SCHEMBL9019827 0.68 NR3C1 (0.59) PGRNR3C1LMNACYP3A4ABCB11
SCHEMBL8541047 0.68 PGR (0.48) PGRNR3C1LMNACYP3A4ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1365765-A2 THE USE OF ANTIGESTAGENS FOR INHIBITING ACCELERATED ENDOMETRIAL MATURATION DURING INFERTILITY TREATMENT SCHERING AKTIENGESELLSCHAFT (DE) 2003-12-03 — — EP disclosed
WO-2002067910-A2 THE USE OF ANTIGESTAGENS FOR INHIBITING ACCELERATED ENDOMETRIAL MATURATION DURING INFERTILITY TREATMENT SCHERING AKTIENGESELLSCHAFT (DE) 2002-09-06 — — WO disclosed
Send feedback